ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Top Stocks Set to Outperform
Over the Next 1 to 3 Months.
Click for your free picks >>

Quote:

Search for Ticker

Free Membership

Search:

POZN: Pozen Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

POZEN INC (NASD)
POZN	7.04	0.02	(0.28%)	Vol. 28,555	11:47 ET

Pozen Inc. is pharmaceutical development company committed to building a portfolio of products with significant commercial potential in select therapeutic areas. Its initial area of focus is migraine, where the company have built a portfolio of four product candidates through a combination of innovation and in-licensing. Its lead product candidate is MT 100, which the company is developing as an oral first-line therapy for the treatment of migraine.

General Information

POZEN INC

1414 Raleigh Road Suite 400 Chapel Hill, NC 27517 Phone: 919 913-1030 Fax: 919 913-1039 Web: www.pozen.com Email: investor@pozen.com

Industry	MED-DRUGS
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	02/24/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	7.02
52 Week High	8.42
52 Week Low	4.50
Beta	1.07
20 Day Moving Average	109,496.65
Target Price Consensus	9.2

% Price Change
4 Week	14.52
12 Week	12.68
YTD	39.29

% Price Change Relative to S&P 500
4 Week	10.14
12 Week	1.71
YTD	14.13

Share Information
Shares Outstanding (millions)	29.83
Market Capitalization (millions)	209.37
Short Ratio	14.77
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.19
Current Year EPS Consensus Estimate	-0.23
Estimated Long-Term EPS Growth Rate	30.00
Next EPS Report Date	02/24/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	2.50
30 Days Ago	2.50
60 Days Ago	2.50
90 Days Ago	2.80

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	184.62%
vs. Previous Quarter	257.14%

Sales Growth
vs. Previous Year	28.22%
vs. Previous Quarter:	190.68%

Price Ratios
Price/Book	5.47
Price/Cash Flow	-
Price / Sales	4.99

ROE
09/30/09	-14.98
06/30/09	-57.34
03/31/09	-5.48

ROA
09/30/09	-8.93
06/30/09	-31.70
03/31/09	-2.94

Current Ratio
09/30/09	3.64
06/30/09	2.77
03/31/09	2.77

Quick Ratio
09/30/09	3.64
06/30/09	2.77
03/31/09	2.77

Operating Margin
09/30/09	-12.28
06/30/09	-50.63
03/31/09	-3.08

Net Margin
09/30/09	-12.29
06/30/09	-50.60
03/31/09	-3.07

Pre-Tax Margin
09/30/09	-12.29
06/30/09	-50.60
03/31/09	-3.07

Book Value
09/30/09	1.28
06/30/09	1.02
03/31/09	1.12

Inventory Turnover
09/30/09	-
06/30/09	-
03/31/09	-

Debt-to-Equity
09/30/09	0.00
06/30/09	0.00
03/31/09	0.00

Debt to Capital
09/30/09	0.00
06/30/09	0.00
03/31/09	0.00


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research